Yann Herault obtained his Ph.D. at the University of Lyon, France and was in the following Post-Doc at the University of Geneva, Switzerland from 1993 to 1999. In 2000 Yann Herault joined the Institute de Transgenose in Orleans, France as a group leader. There he was further the director of the infrastructure for Transgenesis and Archiving of Animal Models (TAAM) from 2007-2014. He developed CELPHEDIA the National Infrastructure for model animal in the French roadmap for Infrastructure (2008-present). Since 2010 Yann Herault is group leader at the IGBMC, Strasbourg, France.
He and his team in the lab on “Translational medicine and neurogenetics” are interested on evaluating the consequences of gene dosage effect and copy number variation in pathological situation such as in Down Syndrome (or Trisomy 21) to further propose new therapeutic approaches.
sources: linkedin, labpage